SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates

SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates


Dapaglifozine, marketed under the name Forxiga®, is an anti-diabetic drug in the glifozin class. It is a SGLT-2 transporter inhibitor that reduces glycated hemoglobin, leads to weight loss and improves blood pressure in patients with type 2 diabetes. Dapaglifozine may be given alone or in combination with insulin, an antihyperglycemic agent, depending on the degree of diabetes.
Since the start of the Covid-19 pandemic, physicians have observed that some patients are at increased risk of developing serious complications that could lead to death. One of the factors that may increase this risk are cardiometabolic diseases such as hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, and heart and kidney failure. Since inhibitors of SGLT-2 transporters have shown strong protective effects on the heart and kidneys in patients with type 2 diabetes, dapaglifozine could protect these vital organ systems in Covid-19.

Search result : 317 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 91
  • Biochemicals 205
  • Inhibitor/Antagonist/Agonist 106
  • Buffers and reagents 6
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
412820-5mg
 5mg 
446234-10mg
 10mg 
446234-50mg
 50mg 
445784-1mg
 1mg 
TRC-D185385-50MG
 50mg 
TRC-D185385-100MG
 100mg 
TRC-D185385-10MG
 10mg 
412820-2.5mg
 2.5mg 
445784-5mg
 5mg 
461231-25mg
 25mg 
461231-100mg
 100mg 
461231-50mg
 50mg 
445787-1mg
 1mg 
445787-10mg
 10mg 
412449-1mg
 1mg 
445786-2.5mg
 2.5mg 
A10285-50
 50mg 
445785-10mg
 10mg